Cenedella.de

Patient Advocate since 1977.


Leave a comment

Canadian pot companies see medical exports growing under Trudeau law

http://www.columbian.com/news/2017/apr/21/canadian-pot-companies-see-medical-exports-growing-under-trudeau-law/

By Josh Wingrove and Jen Skerritt, Bloomberg News

OTTAWA, Canada — Canada’s push to legalize recreational marijuana is rippling beyond its borders as companies move to boost exports of medicinal pot.

Prime Minister Justin Trudeau’s government unveiled its framework last week, quelling concern it would clamp down on export permits for existing medical-pot producers such as Canopy Growth Corp. and Aurora Cannabis Inc. Those companies, which have a head start on the legal recreational market, will continue to be allowed to export marijuana to countries such as Germany and Australia for medical and scientific use.

“It might not be so limited,” said Emily Larose, a partner with law firm Cassels Brock who specializes in cannabis regulation. Industry fears of onerous export restrictions have receded over the past year as bureaucrats typically approve any permit so long as the main requirements are met. “The way in which they’ve been granted so far seems to be more box-ticking.”

Companies in Canada, the second country and first major economy to unveil plans for legalization of recreational pot, have already secured investments and partnerships in countries where support for legalized medical marijuana is gaining ground. The global cannabis market may be worth $200 billion, with the medical market accounting for 25 percent to 50 percent of that, Daniel Pearlstein, a research analyst in Toronto at Eight Capital, said by email.

Canopy is already exporting to Brazil and Germany. Last year, the Smith Falls, Ontario-based company acquired pharmaceutical distributor MedCann GmbH, which has placed its cannabis strains in German pharmacies.

Bedrocan Canada Inc., a unit of Canopy, exported 10 kilograms of dried cannabis to Brazil to be used in a clinical study targeting epilepsy and pain management, according to a November statement.

Canada is emerging as a leader in public policy around marijuana and other countries will need its know-how as they shift toward making cannabis and cannabinoids part of standard medical treatment, said Chief Executive Officer Bruce Linton. That gives Canopy the chance to export product while the domestic industry makes that transition, and to set up production on the ground once it has, he said.

“All of these jurisdictions are contemplating or structuring a way in which production will occur in them,” Linton said by phone. “We are actually an exporter of public policy.”

That meshes with Trudeau’s view for the future of the Canadian economy: one pivoting from raw resource extraction toward white-collar jobs in the services sector.

“You’re going to develop know-how on how to make this stuff,” said Eileen McMahon, a partner at Torys LLP and chair of the law firm’s intellectual property and food and drug regulatory practices. “That know-how arguably could be used” outside Canada under the Trudeau law, she said, adding it’s possible “employees with that expertise could cross the border.”

Aurora intends to be a “significant” player in the Australian market and is looking at others as well, said Cam Battley, an executive vice president. The Cremona, Alberta-based company plans to use its capital and experience to export its product, and to set up in countries where marijuana may soon be legal, he said.

“Canada more broadly is a leader in the cannabis industry,” Battley said by phone. “That gives us a lot of potential power in other markets.”

Exports will be allowed “as long as they meet the strict regulatory requirements,” lawmaker Bill Blair, a former police chief and Trudeau’s point man on pot legalization, said in an interview. He brushed aside questions about whether the government wants to encourage companies to be exporters. “We want to make sure there is a viable industry capable of supplying that well-regulated retail market” domestically in Canada.

The government has to issue export permits repeatedly, and could clamp down, change guidelines or slow its issuing of permits if it wanted to cool the market.

In a notice posted last year, Canada said it “does not support facilitating a regime premised on servicing global demand given the associated public health, safety and security risks” and that export “would be permitted under very limited circumstances.” Fears stoked in industry by that notice have since eased, Larose said.

Aurora secured a 19.9 percent stake last month in Cann Group, the first Australian company to be licensed for research and cultivation of medical cannabis for human use.

Aphria Inc., based in Leamington, Ontario, is investing $25 million in a dispensing operation in Florida, the company said April 4. Aphria’s U.S. expansion strategy is to target key states that have approved medical marijuana, according to the statement.

Canada’s legalization effort may violate its obligations under international law, Steven Hoffman, director of the University of Ottawa’s Global Strategy Lab, wrote in a Globe and Mail editorial this week. “Unless we change our constitution, Canada cannot legally legalize cannabis without either renegotiating the U.N. treaties, obtaining special exceptions, finding creative workarounds, or withdrawing from them,” he wrote.

The government believes its restrictions on production or sale outside its strictly regulated regime, as well as restrictions on some exports and use by minors, keeps it onside, Blair said.

“We believe this enables us to uphold and maintain our obligations under those treaties,” he said, speaking in an interview after Justice Minister Jody Wilson-Raybould referred questions on the matter to Blair.


Leave a comment

Why is Big Pharma fighting Medical Marijuana so hard? A new report published in Health Affairs found that if all states had legalized medical cannabis in 2014, Medicaid could have saved $1 billion in spending on prescriptions…could be one of the reasons.

If all states had had a medical marijuana law in 2014, we estimated that total savings for fee-for-service Medicaid could have been $1.01 billion. 

I write about retail and cannabis.

A new report published in Health Affairs found that if all states had legalized medical marijuana in 2014, Medicaid could have saved $1 billion in spending on prescriptions.

The study by Ashley C. Bradford and W. David Bradford examined whether states with medical marijuana laws saw changes for prescription drugs among Medicare Part D enrollees. Their analysis covered data between 2007 to 2014 and found that patients did indeed substitute medical marijuana for FDA-approved prescription drugs in these states.

“Total estimated Medicaid savings associated with these laws ranged from $260.8 million in 2007 to $475.8 million in 2014,” the study states. Granted this is only 2% of the total Medicaid drug spending for 2014, which was $23.9 billion, but it is still substantial savings. The Bradfords estimate that if all states had legalized medical marijuana in 2014, “The national savings for fee-for-service Medicaid would have been approximately $1.01 billion.” This works out to an average per state savings of $19.825 million a year.

However, only 26% of Medicaid customers are enrolled in the fee-for-service program. The study notes that if they applied their analysis equally to Medicaid managed care, then the savings could jump to a whopping $3.89 billion. Again, this is only if all states legalized medical marijuana.

Granted the savings are mostly enjoyed by private insurers that run the plans, but the Bradfords suggest that state governments could reduce their payments to the insurers as prescription drug costs fall.

The study only looked at conditions that could be treated with medical marijuana and the prescription drugs that would be affected. This included anxiety, depression, glaucoma, nausea, pain, psychosis, seizures, sleep disorders and spasticity. According to the study, “the differences ranged from a 42% reduction for prescriptions used to treat nausea to a 15% reduction for spasticity.” The Bradfords also found a 13% decline in depression drug prescriptions, a 12% drop in psychosis drug prescriptions and an 11% slide in pain drugs. There was no significant drop in drugs used for anxiety, glaucoma or sleep disorders.

The Bradfords noted that their study was challenged by the fact that states keep changing their medical marijuana laws and expanding approved conditions. Furthermore, they only had data available from fee-for-service Medicaid prescriptions. Managed care patient data was inconsistent. Thus, their findings are really lower than what the true savings could really be, suggesting it could be in the billions.


Leave a comment

Import & Export of Medicinal Cannabis Products…to and from Canada.

Blue Diamond Ventures, Inc. a Colorado Corporation ( OTC PINK : BLDV ) today announces that the company has entered into a Joint Development Agreement with Alternative Medical Solutions Inc., to import & export Targeted Medicinal Cannabis Products and Advanced Cannabis Technologies, to and from Canada.

The recent CannaTech Conference in Israel provided the forum to secure the initial agreements required to pursue this effort. Blue Diamond Ventures is not alone; Jeffrey Friedland, noted author and cannabis thought leader, has announced that CannRX is taking a similar approach by partnering to bring Israeli Technologies into the U.S. and other countries. https://israel-cannabis.com/2017/03/22/cannrx-icanisrael-ican-sleep/

Alternative Medical Solutions (AMS) is in the final stage to gain a full license to grow, market and sell medicinal cannabis products via Health Canada. BLDV has been working with AMS over the last year to finalize funding for its Fifty (50) thousand square foot cultivation facility. “There has been recognition, by the Canadian Government, for the need to allow import and export in this industry,” says Joshua B. Alper, CEO of BLDV. “This new effort will ensure that AMS, when licensed, will be a Global Project, with their products being available worldwide and with access to the ingredients and technology that will continue to make AMS a leader in the Canadian market.”

“We are excited to launch this effort with BLDV,” said Joseph Groleau, VP Business Development for AMS. “With the specialized products and technologies coming into Canada from Israel, and access to global markets with our finished products, we see this as a separate profit center that could even outgrow our efforts in cultivation.”

Canada will be the home to the new joint venture, and the first market focus will be to bring Israeli Cannabis products and technology to Canada. “AMS is the perfect partner for this project,” said Joshua B. Alper, CEO of Blue Diamond Ventures, Inc. “They have a great team at AMS that has been challenged by the ever-shifting landscape of compliance and financial requirements, this project can create significant revenue even prior to AMS receiving the cultivation and manufacturing licenses from Health Canada.” BLDV senior project manager, Jonathan B. Alper, who is fluent in Hebrew and has been involved in import and export of products from Israel, to Canada, and the U.S. for over 25 years, will manage the effort in cooperation with a team of license and compliance experts in Canada.

In other news:

BLDV has filed its Annual Report on the OTC Markets and has recently secured employment contracts with all key personnel for common stock, without the need to raise authorized common stock levels, or issue special warrants, options and/or preferred stock.

About BLDV:

Blue Diamond Ventures, Inc. seeks to partner with individuals and companies that share a common synergy, mission, and vision to enable products/services that are produced, delivered and consumed utilizing fewer natural resources, providing a sustainable alternative to traditional products on the market today. As a diversified customer centric Management / Holding Company; Blue Diamond Ventures, Inc. seeks opportunities in various markets and is driven by critical thinking and the scientific method.

About AMS:

Alternative Medical Solutions (“AMS”) is in the process of becoming a Licensed Producer of Medical Marijuana in Canada and is led by a highly passionate team dedicated to being at the forefront of the growing Medical Marijuana industry.

Safe Harbor:

This press release contains forward-looking statements. Such forward-looking statements are subject to several risks, assumptions, and uncertainties that could cause the Company’s actual results to differ materially from those projected in such statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly revise any forward-looking statements.


1 Comment

BERLIN PEACE ACCORDS – “putting an end to the world war on Cannabis!”

April 20th NEWS ALERT:

The BERLIN PEACE ACCORDS, “putting an end to the world war on Cannabis” were ratified last week and are now available for your signature at http://www.berlinpeaceaccords.de

This is your chance to add your name to this historic document and tell the Presidents of the United States, the United Nations, the European Union as well as Chancellor Merkel of Germany that the world war on Cannabis needs to end in 2017.

Please sign petition at http://www.berlinpeaceaccords.com and share with others so inclined.
Thank you, Gracias und Dankeschoene!

BERLIN PEACE ACCORDS

We the people of the Year 2017 do…
Hereby declare that it is our inalienable basic human right to have the freedom to grow, medicate and enjoy the plant we call Cannabis, without any governmental limitations.
We demand our plant has no more regulations or limitations than a tomato plant.
It is our basic human right to have control of what we choose to put into our body.
It is our basic human right to have the ability to enjoy this plant without fear of incarceration or limitations on its commerce.
It is our basic human right to have multiple ways to enjoy, grow and medicate with our plant and we demand that no commercial organization be provided exclusive use or rights.
For 10,000 years humans on our planet have enjoyed the benefits provided by our plant. With my signature below I do hereby attest it is my wish that “we the people” have the right to consume our plant as we wish.
———————
Wir, die Menschheit des Jahres 2017…
Erklären hiermit unser unveräußerliches Menschenrecht auf Anbau, Medikation und Konsum der Pflanze mit dem Namen Cannabis ohne jegliche staatliche Einschränkung. Verlangen, dass unsere Pflanze keine anderen Auflagen und
Einschränkungen als eine Tomatenpflanze hat. Stellen unter unsere eigene Kontrolle, was wir unserem Körper zuführen. Bestehen auf unser Grundrecht, diese Pflanze zu benutzen ohne die Androhung von Freiheitsberaubung und ohne Nutzungsbeschränkungen.
Es ist unser Grundrecht, auf verschiedenste Arten Zugang zu Cannabis zu haben und keine kommerziellen Interessenverbände das Recht auf exklusive Nutzung oder Rechtsanspruch erhalten. Seit Urzeiten haben die Menschen die Segnungen unserer Pflanze genutzt.
Mit meiner Unterschrift lege ich hiermit Zeugnis ab über meinem Wunsch, dass „wir, die Menschen“ das Recht besitzen, unsere Pflanze nach unseren Wünschen zu benutzen.


1 Comment

BERLIN PEACE ACCORDS – putting an end to the world war on Cannabis.

BERLIN PEACE ACCORDS

12 April 2017

Berlin, Germany

FOR IMMEDIATE RELEASE:

On the closing day of the International Cannabis Business Conference in Berlin, advocates from throughout the world ratified the BERLIN PEACE ACCORDS that call for an immediate end to the world war on cannabis.

On July 7, 2017 these Accords will be presented to President Donald Trump of the United States and Chancellor Angela Merkel of Germany at their summit meeting in Hamburg, Germany. In advance of that date, advocates worldwide will be showing their support by simply “liking” it on the facebook page: https://www.facebook.com/Berlin-PEACE-Accords-1899471536976478/

Citizens of the world who are in support of the BERLIN PEACE ACCORDS are urged to print these Accords off, sign them, place them at your home or office, and share them with others.

In addition, advocates will be re-posting these Accords on their respective facebook pages (and other social media) to have their members, customers, colleagues “like” the Accords as well.

If you are interested in becoming a “link on the chain” to peace or have any questions, please feel free to contact phil@cenedella.de for additional information or to support our efforts in anyway.

President Trump and Chancellor Merkel are interested to know if people in the year 2017 really feel this way.

Now is the time for you to show you do.

peace,

The Advocates of the

BERLIN PEACE ACCORDS

We the people of the Year 2017 do…

Hereby declare that it is our inalienable basic human right to have the freedom to grow, medicate and enjoy the plant we call Cannabis, without any governmental limitations.

We demand our plant has no more regulations or limitations than a tomato plant.
It is our basic human right to have control of what we choose to put into our body.

It is our basic human right to have the ability to enjoy this plant without fear of incarceration or limitations on its commerce.

It is our basic human right to have multiple ways to enjoy, grow and medicate with our plant and we demand that no commercial organization be provided exclusive use or rights.
For 10,000 years humans on our planet have enjoyed the benefits provided by our plant. With my signature below I do hereby attest it is my wish that “we the people” have the right to consume our plant as we wish.

LIKE THIS PAGE @
https://www.facebook.com/Berlin-PEACE-Accords-1899471536976478/

Thank you, Gracias und Dankeschoene,
phil


Leave a comment

A bipartisan Congressional Delegation that includes New York Congressman Brian Higgins and California Congressman Dana Rohrabacher have scheduled a trip to Europe next week to study their various legal cannabis policies and regulatory systems, reports Marijuana Politics. – ICBC BERLIN

http://blog.sfgate.com/smellthetruth/2017/04/03/u-s-congressmen-headed-to-europe-to-discuss-legal-pot-industry/

The pressure to legalize marijuana worldwide has become so much so that U.S. lawmakers are taking a pot-filled field trip to Europe.

A bipartisan Congressional Delegation that includes New York Congressman Brian Higgins and California Congressman Dana Rohrabacher have scheduled a trip to Europe next week to study their various legal cannabis policies and regulatory systems, reports Marijuana Politics.

The delegation’s multi-country tour will be highlighted by a stop in Germany, where medical marijuana was legalized earlier this year. The congressmen are scheduled to speak at the International Cannabis Business Conference (ICBC) in Berlin.

The international cannabis business community is bracing for the onset of import/export and cross-border deals allowing countries with favorable federal legal standing to get a jump on countries such as the U.S., whose federal laws currently impede many such deals, along with medical research, which is the basis of many products and intellectual property.

Republican Rep. Dana Rohrabacher, a candid medical marijuana user who has long fought for legal cannabis reform in California, is scheduled to deliver the event’s keynote speech on April 12.

“This is an exciting time for drug policy reform,” Rohrabacher told Marijuana Politics. “I haven’t witnessed this scale of reform in the world since I worked with Ronald Reagan in 1987, when he uttered those famous words: ‘Mr. Gorbachev tear down this wall.’ Now, almost 30 years later, the Berlin Wall of medical marijuana prohibition is crumbling.”